A phase 2b clinical trial of CLS-AX, a tyrosine kinase inhibitor under evaluation for the treatment of wet age-related macular degeneration, achieved its primary and secondary outcomes, according to a Clearside Biomedical press release.
“Importantly, our data support that CLS-AX has the potential to be a well-tolerated treatment that can provide patients and retina specialists with a flexible maintenance dosing regimen between 3 to 6 months,” Victor Chong, MD, MBA, chief medical officer of Clearside, told Healio.
The randomized, double-masked, parallel-group, active-controlled,